Massively parallel single cell analysis
The disclosure provides for methods, compositions, and kits for multiplex nucleic acid analysis of single cells. The methods, compositions and systems may be used for massively parallel single cell sequencing. The methods, compositions and systems may be used to analyze thousands of cells concurrently. The thousands of cells may comprise a mixed population of cells (e.g., cells of different types or subtypes, different sizes).
1. A composition, comprising:
a plurality of particles each associated with a plurality of oligonucleotides, wherein each of the plurality of oligonucleotides comprises a cellular label sequence, a molecular label sequence, and a target-binding region at 3′ of the cellular label sequence and the molecular label sequence, wherein the cellular label sequence of each of the plurality of oligonucleotides is the same on the same particle but different on the different particle, and wherein at least 100 of the plurality of oligonucleotides associated with each of the plurality of particles comprise different molecular label sequences.
2. The composition of claim 1 , wherein each of the plurality of particles is associated with a plurality of peptides.
3. The composition of claim 2 , wherein the plurality of peptides comprises a plurality of antibodies.
4. The composition of claim 3 , further comprising a plurality of single cells, wherein at least one of the plurality of antibodies bind to the surface of at least one of the plurality of single cells.
5. The composition of claim 4 , wherein the plurality of oligonucleotides of each of the plurality of particles is capable of labeling individual occurrences of target molecules of one of the plurality of single cells.
6. The composition of claim 4 , wherein the plurality of oligonucleotides of each of the plurality of particles is capable of labeling individual occurrences of mRNA molecules of one of the plurality of single cells via reverse transcription.
7. The composition of claim 2 , wherein the target-binding region comprises a sequence selected from the group consisting of an oligo-dT sequence, a gene-specific sequence, and a random multimer sequence.
8. The composition of claim 4 , wherein at least one of the plurality of single cells is selected from the group consisting of a rare cell, a tumor cell, a human cell, a cell from a tissue, a tumor cell, an immune cell, a cell infected with viral polynucleotides, and any combination thereof.
9. The composition of claim 2 , wherein each of the plurality of oligonucleotides further comprises at least one of: (a) a sample label sequence; and (b) a universal label sequence.
10. The composition of claim 2 , wherein each of the plurality of particles comprises a material selected from the group consisting of polydimethylsiloxane (PDMS), polystyrene, glass, polypropylene, agarose, gelatin, hydrogel, paramagnetic, ceramic, plastic, glass, methylstyrene, acrylic polymer, titanium, latex, sepharose, cellulose, nylon, silicone, and any combination thereof.
11. The composition of claim 2 , wherein each of the plurality of particles is a bead.
12. The composition of claim 11 , wherein the bead is selected from the group consisting of streptavidin beads, agarose beads, magnetic beads, antibody conjugated beads, protein A conjugated beads, protein G conjugated beads, protein NG conjugated beads, protein L conjugated beads, oligodT conjugated beads, silica beads, silica-like beads, anti-biotin microbead, and anti-fluorochrome microbead.
13. The composition of claim 11 , wherein the bead comprises hydrogel or a polymer.
14. The composition of claim 11 , wherein the bead comprises silica gel, controlled pore glass, Dynabead, Wang resin, Merrifield resin, Sephadex/Sepharose bead, cellulose bead, polystyrene bead, or any combination thereof.
15. The composition of claim 11 , wherein the bead is semi-solid.
16. The composition of claim 2 , wherein at least 1,000 of the plurality of oligonucleotides associated with each of the plurality of particles comprise different molecular label sequences.
17. The composition of claim 2 , wherein at least 10,000 of the plurality of oligonucleotides associated with each of the plurality of particles comprise different molecular label sequences.
18. The composition of claim 2 , wherein the plurality of oligonucleotides comprises at least 100,000 oligonucleotides.
19. The composition of claim 2 , wherein the molecular label sequences comprise random sequences.
20. The composition of claim 3 , wherein the plurality of antibodies is conjugated to the particle.
21. The composition of claim 3 , wherein the plurality of antibodies is attached to the plurality of oligonucleotides.